Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

• Status: Not yet recruiting
• Trial end date: 2026-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Elgan Pharma Ltd.

Criteria

Inclusion Criteria:

• Male or female pre-term infant 26 and up to 32 weeks gestation. Gestational age matching (±2 weeks) between maternal dates and/or early antenatal ultrasound

• Birth weight ≥ 500g

• Singleton or twin birth

Exclusion Criteria:

-